ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Analysts give ProQR a “Moderate Buy” consensus: Six of eight analysts rate the stock a buy, while one rates it hold and one sell. The average 12-month price target is $7.60.
• Recent quarterly results beat expectations: ProQR reported a loss of $0.09 per share versus a forecast loss of $0.13, and revenue of $10 million compared with a $4.56 million consensus estimate.
• PRQR opened at $1.26, near its 52-week low of $1.20; its 52-week high is $2.48.

ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eight research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $7.60.

PRQR has been the subject of a number of recent research reports. Weiss Ratings raised ProQR Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 14th. Wall Street Zen upgraded shares of ProQR Therapeutics from a "strong sell" rating to a "hold" rating in a report on Saturday, August 15th. HC Wainwright lowered their price objective on shares of ProQR Therapeutics to $8.00 and set a "buy" rating on the stock in a report on Thursday, October 1st. Bank of America assumed coverage on shares of ProQR Therapeutics in a research report on Thursday, August 20th. They issued a "buy" rating and a $8.00 price objective on the stock. Finally, Chardan Capital restated a "buy" rating and set a $3.00 target price on shares of ProQR Therapeutics in a report on Thursday, October 1st.

ProQR Therapeutics Price Performance

PRQR stock opened at $1.26 on Thursday. The stock has a market capitalization of $132.76 million, a P/E ratio of -2.74 and a beta of 0.29. The business has a 50-day moving average of $1.60 and a 200-day moving average of $1.68. ProQR Therapeutics has a fifty-two week low of $1.20 and a fifty-two week high of $2.48.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.04. ProQR Therapeutics had a negative return on equity of 73.83% and a negative net margin of 223.51%. The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $4.56 million. Equities analysts expect that ProQR Therapeutics will post -0.45 EPS for the current year.

Hedge Funds Weigh In On ProQR Therapeutics

Large investors have recently modified their holdings of the business. Walleye Capital LLC grew its holdings in shares of ProQR Therapeutics by 2.7% in the 1st quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company's stock valued at $984,000 after acquiring an additional 15,744 shares in the last quarter. Bank of America Corp DE raised its holdings in ProQR Therapeutics by 6.4% during the first quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company's stock worth $300,000 after acquiring an additional 11,186 shares in the last quarter. RFG Advisory LLC raised its holdings in ProQR Therapeutics by 236.8% during the second quarter. RFG Advisory LLC now owns 64,000 shares of the biopharmaceutical company's stock worth $119,000 after acquiring an additional 45,000 shares in the last quarter. Axiom Investment Management LLC acquired a new position in ProQR Therapeutics during the first quarter valued at approximately $53,000. Finally, Alpha Wealth Funds LLC acquired a new position in ProQR Therapeutics during the third quarter valued at approximately $41,000. 32.65% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA therapies for genetic diseases. The company uses its Axiomer RNA-editing platform to investigate treatments designed to correct disease-causing genetic changes at the RNA level without permanently altering DNA. ProQR's research has included therapies for rare inherited disorders, particularly genetic diseases affecting the eye and nervous system. Its development programs have included investigational treatments for inherited retinal diseases, while the company has also pursued partnerships and licensing opportunities to advance RNA-editing applications across additional disease areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.